Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brigimadlin - Boehringer Ingelheim

Next Previous
Drug Profile

Brigimadlin - Boehringer Ingelheim

Alternative Names: BI 907828; MDM2-p53 antagonist - Boehringer Ingelheim

Latest Information Update: 29 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liposarcoma
  • Phase II Biliary cancer; Bladder cancer; Lung cancer; Pancreatic cancer
  • Phase I Glioblastoma; Solid tumours

Most Recent Events

  • 12 Dec 2023 Phase-III clinical trials in Liposarcoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, First-line therapy) in USA (PO) (NCT06058793)
  • 30 Oct 2023 Burning Rock signs a master service agreement with Boehringer Ingelheim for oncology companion diagnostics for the treatment of cancer in China
  • 30 Oct 2023 National Medical Products Administration of China approves clinical trial application for Brigimadlin in Solid tumours, prior to October 2023
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top